BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9209418)

  • 1. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
    Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
    Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients.
    Salles G; Bienvenu J; Bastion Y; Barbier Y; Doche C; Warzocha K; Gutowski MC; Rieux C; Coiffier B
    Br J Haematol; 1996 May; 93(2):352-9. PubMed ID: 8639428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients].
    Núñez-González JR; Sanabria-Vera CJ; Romero-Adrián T
    Invest Clin; 2001 Sep; 42(3):171-81. PubMed ID: 11552506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
    Warzocha K; Bienvenu J; Ribeiro P; Moullet I; Dumontet C; Neidhardt-Berard EM; Coiffier B; Salles G
    Br J Cancer; 1998 Jun; 77(12):2357-62. PubMed ID: 9649158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
    Robak T; Gladalska A; Stepień H
    Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
    Li D; Li G; Wang B
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
    Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
    Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer.
    Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Prato B; Prontera C; Facchini V; Genazzani AR
    Anticancer Res; 1996; 16(5B):3125-8. PubMed ID: 8920779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Importance of determination of serum beta-2-microglobulin levels in patients with Hodgkin's lymphoma].
    Raida L; Papajík T; Hlusí A; Faber E; Urbanová R; Heczko M; Jancíková M; Zapletalová J; Komenda S; Indrák K
    Vnitr Lek; 2002 Feb; 48(2):91-5. PubMed ID: 11949228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
    Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A
    Haematologica; 2004 May; 89(5):552-6. PubMed ID: 15136218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].
    Fleury J; Tortochaux J; Legros M; Cure H; Kwiatkowski F; Ferrière JP; Travade P; Dionet C; Gaillard G; Chassagne J
    Bull Cancer; 1994 Jul; 81(7):625-31. PubMed ID: 7742606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of some biochemical markers as prognostic factors in malignant lymphomas.
    Salem HA; Eissa LA; Rabbie AM; El-Helw LM; El-Gayar AM
    Pak J Pharm Sci; 2006 Jul; 19(3):219-30. PubMed ID: 16935830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock.
    Iglesias J; Marik PE; Levine JS;
    Am J Kidney Dis; 2003 Jan; 41(1):62-75. PubMed ID: 12500222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
    Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
    Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.